Baidu
map

Am J Rhinol Allergy:非过敏性鼻炎患者的临床特性区分

2019-05-23 AlexYang MedSci原创

并不是所有的鼻炎患者均受免疫球蛋白E(lgE)调控的炎症过程影响。由于皮刺和血清过敏原评估受限,因而不能对局部过敏性鼻炎(LAR)进行确诊。因此,具有阴性系统性过敏评估的患者其实包括了非过敏性鼻炎患者(NAR)和LAR患者。最近,有研究人员确定了NAR患者的临床特性。研究是一个代表性的研究,包括了154名参与者(平均年龄为41.79±14.78岁,37.7%的为女性 )。与AR患者相比,NAR患者

并不是所有的鼻炎患者均受免疫球蛋白E(lgE)调控的炎症过程影响。由于皮刺和血清过敏原评估受限,因而不能对局部过敏性鼻炎(LAR)进行确诊。因此,具有阴性系统性过敏评估的患者其实包括了非过敏性鼻炎患者(NAR)和LAR患者。最近,有研究人员确定了NAR患者的临床特性。

研究是一个代表性的研究,包括了154名参与者(平均年龄为41.79±14.78岁,37.7%的为女性 )。与AR患者相比,NAR患者(11.7%)年龄更大(49.33±15.99 vs 40.78±14.38岁, P=0.02),具有更少的自我报道的哮喘(5.6% vs 36.3%, P<0.01)和屋尘螨激发的过敏(38.9 vs 65.2%, P=0.03)。另外,CII得分在NAR和AR患者中相似(31.06±28.88 vs 35.49±24.70, P=0.61)。

最后,研究人员指出,那些年龄更大,没有哮喘和没有吸入过敏激发的参与者更可能是NAR患者。环境激发并不是NAR的区分特性。这些结果也许可以作为鉴定鼻炎患者的指导。

原始出处:

Hamizan AW, Azer M, Alvarado R et al. The Distinguishing Clinical Features of Nonallergic Rhinitis Patients. Am J Rhinol Allergy. 20 May 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047120, encodeId=bd04204e120cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Oct 17 12:05:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955713, encodeId=16391955e1374, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Jan 26 23:05:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044937, encodeId=d298204493e52, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Dec 21 23:05:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329244, encodeId=71e71329244b4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat May 25 04:05:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047120, encodeId=bd04204e120cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Oct 17 12:05:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955713, encodeId=16391955e1374, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Jan 26 23:05:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044937, encodeId=d298204493e52, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Dec 21 23:05:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329244, encodeId=71e71329244b4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat May 25 04:05:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047120, encodeId=bd04204e120cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Oct 17 12:05:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955713, encodeId=16391955e1374, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Jan 26 23:05:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044937, encodeId=d298204493e52, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Dec 21 23:05:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329244, encodeId=71e71329244b4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat May 25 04:05:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047120, encodeId=bd04204e120cb, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Oct 17 12:05:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955713, encodeId=16391955e1374, content=<a href='/topic/show?id=4f6599e04e9' target=_blank style='color:#2F92EE;'>#非过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99704, encryptionId=4f6599e04e9, topicName=非过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sun Jan 26 23:05:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044937, encodeId=d298204493e52, content=<a href='/topic/show?id=3dd62288e2b' target=_blank style='color:#2F92EE;'>#临床特性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22887, encryptionId=3dd62288e2b, topicName=临床特性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Dec 21 23:05:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329244, encodeId=71e71329244b4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat May 25 04:05:00 CST 2019, time=2019-05-25, status=1, ipAttribution=)]
    2019-05-25 膀胱癌

相关资讯

Int J Pediatr Otorhinolaryngol:原发性打鼾和阻塞性睡眠呼吸暂停综合征儿童鼻腔细胞学分析

鼻炎根据病因(感染或者过敏原过敏)的不同包括慢性炎症和急性炎症。鼻腔炎症在原发性打鼾和阻塞性睡眠呼吸暂停综合征中的作用结果还存在争议。最近,有研究人员调查了1-15岁的58名儿童的鼻腔细胞学情况,他们均受睡眠障碍性呼吸影响。研究人员发现,在88%的儿童中发现了鼻粘膜的炎症。其中最常见的为传染性的鼻炎(36%),其次是非过敏性鼻炎(28%)和过敏性鼻炎(21%)。在原发性打鼾儿童中,传染性鼻炎占比3

Environ Int:家庭清洗剂的使用和呼吸道与过敏症状研究

有研究指出,家庭中使用清洗剂的成年人的哮喘和过敏性症状风险更高。在青少年中,哮喘和过敏性症状与清洗剂之间的相关性还没有调查。最近,有研究人员在青少年中调查了家庭清洗剂的使用与哮喘、鼻炎和湿疹患病率之间的关系。研究是一个代表性的研究,数据包括了10种清洗剂和有关哮喘、鼻炎和湿疹的信息(n=2333,年龄14)。研究发现,年龄为14岁的参与者中,哮喘、鼻炎和湿疹的患病率分别为7%、13%和11%。家庭

Allergy Asthma Proc:奥洛他定-莫米松组合鼻喷剂在季节过敏性鼻炎患者中的效果和安全性评估

GSP301是一种研究用的固定剂量组合鼻喷剂,其中包含了抗组胺剂、盐酸洛普他定(HCI)和皮质类固醇糠酸莫米他松。最近,有研究人员评估了GSP301在季节过敏性鼻炎(SAR)患者中的效果和安全性。研究是一个双盲、随机和平行的研究。研究总共包括了1180名患者。在经过14天的治疗后,与安慰剂组(最小平方平均差-0.98;95%CI,-1.38到-0.57;p<0.001)和奥洛他定治疗组(p=

EBioMedicine:IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

自身免疫和过敏与调节T细胞(Tregs)数目的减少和低水平的白介素-2(IL-2)相关。最近,有研究人员调查了在童年早期,是否病原气道细菌刺激外周血单核细胞(PBMCs)而释放的IL-2与过敏结果的发展相关。研究人员从331名6月大的婴幼儿中分离了PBMCs细胞,之后在体外利用流感嗜血杆菌、卡他拉氏杆菌和肺炎链球菌对PBMCs细胞进行刺激。之后,利用电化学荧光免疫反应对各种细胞因子(IL-2, I

盘点:鼻炎研究小结

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Clin Exp Otorhinolaryngol:长期母乳喂养在预防过敏性鼻炎中的作用分析 https://www.ncbi.nlm.nih.gov/pubmed/309

盘点:鼻炎治疗研究小结

【1】Clin Exp Otorhinolaryngol:虎耳草在过敏性鼻炎中的抗过敏作用研究 https://www.ncbi.nlm.nih.gov/pubmed/30942049虎耳草提取物具有抗癌、抗过敏和抗氧化活性。最近,有研究人员调查了虎耳草提取物对过敏性鼻炎炎症中的作用。研究包括了4个不同的小组(组A:对照组;组B:过敏性鼻炎组;组C:300mg/kg处理组;组D:600mg/k

Baidu
map
Baidu
map
Baidu
map